PMC:7405836 / 115443-116209
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T38 | 551-556 | Body_part | denotes | serum | http://purl.org/sig/ont/fma/fma63083 |
T39 | 660-666 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
LitCovid-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T129 | 551-556 | Body_part | denotes | serum | http://purl.obolibrary.org/obo/UBERON_0001977 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T1028 | 164-172 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T1029 | 717-725 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T111 | 300-305 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
T112 | 452-455 | http://purl.obolibrary.org/obo/CLO_0001180 | denotes | 203 |
T113 | 458-459 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T114 | 470-476 | http://purl.obolibrary.org/obo/NCBITaxon_33208 | denotes | animal |
T115 | 574-580 | http://purl.obolibrary.org/obo/NCBITaxon_9837 | denotes | camels |
T116 | 660-666 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T232 | 277-287 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
T233 | 397-407 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T783 | 0-96 | Sentence | denotes | Further assessment is necessary before confirming the effectiveness of such combination therapy. |
T784 | 97-246 | Sentence | denotes | In addition, to prevent further community and nosocomial spread of COVID-19, the postprocedure risk management program should not be neglected (309). |
T785 | 247-457 | Sentence | denotes | Development of broad-spectrum inhibitors against the human coronaviral pathogens will help to facilitate clinical trials on the effectiveness of such inhibitors against endemic and emerging coronaviruses (203). |
T786 | 458-618 | Sentence | denotes | A promising animal study revealed the protective effect of passive immunotherapy with immune serum from MERS-immune camels on mice infected with MERS-CoV (204). |
T787 | 619-766 | Sentence | denotes | Passive immunotherapy using convalescent plasma is another strategy that can be used for treating COVID-19-infected, critically ill patients (205). |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
3151 | 300-305 | Species | denotes | human | Tax:9606 |
3152 | 306-317 | Species | denotes | coronaviral | Tax:11118 |
3153 | 437-450 | Species | denotes | coronaviruses | Tax:11118 |
3154 | 574-580 | Species | denotes | camels | Tax:9838 |
3155 | 584-588 | Species | denotes | mice | Tax:10090 |
3156 | 603-611 | Species | denotes | MERS-CoV | Tax:1335626 |
3157 | 751-759 | Species | denotes | patients | Tax:9606 |
3158 | 164-172 | Disease | denotes | COVID-19 | MESH:C000657245 |
3159 | 589-597 | Disease | denotes | infected | MESH:D007239 |
3160 | 717-734 | Disease | denotes | COVID-19-infected | MESH:C000657245 |
3161 | 736-750 | Disease | denotes | critically ill | MESH:D016638 |